Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmacyte Biotech Inc (NQ: PMCB )

1.700 -0.050 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmacyte Biotech Inc

< Previous 1 2 3 4 Next >
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate
PharmaCyte Biotech Inc (NASDAQ: PMCB) updated its activities to lift the FDA's clinical hold on PharmaCyte's treatment for locally advanced, inoperable... 
Via Benzinga
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Epizyme (NASDAQ:EPZM) shares incr... 
Via Benzinga
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
From PharmaCyte Biotech, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market session. The company's market cap stands at $37.7... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the... 
Via Benzinga
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
From PharmaCyte Biotech, Inc.
Via Business Wire
Why Are PharmaCyte Shares Moving Higher On Thursday?
PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of its CypCaps trial product candidate. These... 
Via Benzinga
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
From PharmaCyte Biotech, Inc.
Via Business Wire
41 Stocks Moving In Friday's Mid-Day Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
60 Biggest Movers From Friday
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?
The stock price of PharmaCyte Biotech Inc (NASDAQ: PMCB) is trading higher during premarket today. Investors are expecting a major announcement from the company... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff... 
Via Benzinga
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
From PharmaCyte Biotech, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
From PharmaCyte Biotech, Inc.
Via Business Wire
35 Stocks Moving In Monday's Mid-Day Session
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value... 
Via Benzinga
25 Stocks Moving in Monday's Pre-Market Session
Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.